Citations (49)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
L. Schmidt, O. Sehic & C. Wild. (2022) Counting the cost of public and philanthropic R&D funding: the case of olaparib. Journal of Pharmaceutical Policy and Practice 15:1.
Read now
Read now
Laurence Booth, Nichola Cruickshanks, Thomas Ridder, Yun Dai, Steven Grant & Paul Dent. (2013) PARP and CHK inhibitors interact to cause DNA damage and cell death in mammary carcinoma cells. Cancer Biology & Therapy 14:5, pages 458-465.
Read now
Read now
Laura Orlando, Paola Schiavone, Palma Fedele, Nicola Calvani, Angelo Nacci, Margherita Cinefra, Maria D'Amico, Enrica Mazzoni, Antonella Marino, Francesco Sponziello, Franco Morelli, Lucia Lombardi, Nicola Silvestris & Saverio Cinieri. (2012) Poly (ADP-ribose) polymerase (PARP): rationale, preclinical and clinical evidences of its inhibition as breast cancer treatment. Expert Opinion on Therapeutic Targets 16:sup2, pages S83-S89.
Read now
Read now
Nupur N. Gangopadhyay, James D. Luketich, Amy Opest, Carmen Visus, Ernest M. Meyer, Rodney Landreneau & Matthew J. Schuchert. (2011) Inhibition of Poly(ADP-Ribose) Polymerase (PARP) Induces Apoptosis in Lung Cancer Cell Lines. Cancer Investigation 29:9, pages 608-616.
Read now
Read now
V Kruse, S Rottey, O De Backer, S Van Belle, V Cocquyt & H Denys. (2011) PARP INHIBITORS IN ONCOLOGY: A NEW SYNTHETIC LETHAL APPROACH TO CANCER THERAPY. Acta Clinica Belgica 66:1, pages 2-9.
Read now
Read now
Carlos W. Nossa & Steven R. Blanke. (2010) Helicobacter pylori activation of PARP-1. Gut Microbes 1:6, pages 373-378.
Read now
Read now
Articles from other publishers (43)
Samir A. Farghaly. 2022. Advances in Diagnosis and Management of Ovarian Cancer. Advances in Diagnosis and Management of Ovarian Cancer
179
203
.
Navnath P. Karche, Mandar Bhonde, Neelima Sinha, Gourhari Jana, Gagan Kukreja, Sanjay P. Kurhade, Arun R. Jagdale, Ajay R. Tilekar, Anil K. Hajare, Ganesh R. Jadhav, Nishant R. Gupta, Rohan Limaye, Nilesh Khedkar, Baban R. Thube, Javed S. Shaikh, Nageswara Rao Irlapati, Samiron Phukan, Gopal Gole, Apparao Bommakanti, Harshal Khanwalkar, Yogesh Pawar, Ramesh Kale, Rakesh Kumar, Rajesh Gupta, V.R. Praveen Kumar, Saif Wahid, Albi Francis, Tariq Bhat, Nivrutti Kamble, Vinod Patil, Prashant B. Nigade, Dipak Modi, Shashikant Pawar, Sneha Naidu, Harish Volam, Vamsi Pagdala, Sadanand Mallurwar, Hemant Goyal, Pushpak Bora, Prajakta Ahirrao, Minakshi Singh, Prabhakaran Kamalakannan, Kumar Ram Naik, Pradipta Kumar, Rajendra G. Powar, Rajesh B. Shankar, Peter R. Bernstein, Jayasagar Gundu, Kumar Nemmani, Lakshmi Narasimham, Kochumalayil Shaji George, Sharad Sharma, Dhananjay Bakhle, Rajender Kumar Kamboj & Venkata P. Palle. (2020) Discovery of isoquinolinone and naphthyridinone-based inhibitors of poly(ADP-ribose) polymerase-1 (PARP1) as anticancer agents: Structure activity relationship and preclinical characterization. Bioorganic & Medicinal Chemistry 28:24, pages 115819.
Crossref
Crossref
Chaoguo Cao, Jie Yang, Yong Chen, Peiting Zhou, Yingwei Wang, Wu Du, Lifeng Zhao & Yuanwei Chen. (2020) Discovery of SK-575 as a Highly Potent and Efficacious Proteolysis-Targeting Chimera Degrader of PARP1 for Treating Cancers. Journal of Medicinal Chemistry 63:19, pages 11012-11033.
Crossref
Crossref
Jyotika Rajawat, Nidhi Shukla & Durga Prasad Mishra. (2017) Therapeutic Targeting of Poly(ADP-Ribose) Polymerase-1 (PARP1) in Cancer: Current Developments, Therapeutic Strategies, and Future Opportunities. Medicinal Research Reviews 37:6, pages 1461-1491.
Crossref
Crossref
Gilberto S. Almeida, Carlo M. Bawn, Martin Galler, Ian Wilson, Huw D. Thomas, Suzanne Kyle, Nicola J. Curtin, David R. Newell & Ross J. Maxwell. (2017) PARP inhibitor rucaparib induces changes in NAD levels in cells and liver tissues as assessed by MRS. NMR in Biomedicine 30:9, pages e3736.
Crossref
Crossref
Yvonne L.E. Ang & David S.P. Tan. (2017) Development of PARP inhibitors in gynecological malignancies. Current Problems in Cancer 41:4, pages 273-286.
Crossref
Crossref
Yoshiyuki KANAI. (2016) Overview on poly(ADP-ribose) immuno-biomedicine and future prospects. Proceedings of the Japan Academy, Series B 92:7, pages 222-236.
Crossref
Crossref
Mahesh Hegde, Kempegowda Mantelingu, Hassan A. Swarup, Chottanahalli S. Pavankumar, Imteyaz Qamar, Sathees C. Raghavan & Kanchugarakoppal S. Rangappa. (2016) Novel PARP inhibitors sensitize human leukemic cells in an endogenous PARP activity dependent manner. RSC Advances 6:8, pages 6308-6319.
Crossref
Crossref
Michael Dean, Joseph Boland, Meredith Yeager, Kate M. Im, Lisa Garland, Maria Rodriguez-Herrera, Mylen Perez, Jason Mitchell, David Roberson, Kristine Jones, Hyo Jung Lee, Rebecca Eggebeen, Julie Sawitzke, Sara Bass, Xijun Zhang, Vivian Robles, Celia Hollis, Claudia Barajas, Edna Rath, Candy Arentz, Jose A. Figueroa, Diane D. Nguyen & Zeina Nahleh. (2015) Addressing health disparities in Hispanic breast cancer: accurate and inexpensive sequencing of BRCA1 and BRCA2. GigaScience 4:1.
Crossref
Crossref
Miaomiao Niu, Ke Wang, Congying Zhang, Xinyue Dong, Fang Li, Fengzhen Wang, Yaru Dong, Xue Dong & Yueqing Gu. (2015) Poly(ADP-ribose) polymerase (PARP)-based pharmacophore model development and its application in designing antitumor inhibitors. Journal of the Taiwan Institute of Chemical Engineers 48, pages 1-7.
Crossref
Crossref
Jin Zhang, Dongmei Yin & Hongxia Li. (2014) hMSH2 expression is associated with paclitaxel resistance in ovarian carcinoma, and inhibition of hMSH2 expression in�vitro restores paclitaxel sensitivity. Oncology Reports.
Crossref
Crossref
Wenqi Wu, Hanliang Zhu, Yeping Liang, Zhenzhen Kong, Xiaolu Duan, Shujue Li, Zhijian Zhao, Dong Yang & Guohua Zeng. (2014) Expression of PARP-1 and its active polymer PAR in prostate cancer and benign prostatic hyperplasia in Chinese patients. International Urology and Nephrology 46:7, pages 1345-1349.
Crossref
Crossref
Jung-Min Lee, John L. Hays, Christina M. Annunziata, Anne M. Noonan, Lori Minasian, Jo Anne Zujewski, Minshu Yu, Nicolas Gordon, Jiuping Ji, Tristan M. Sissung, William D. Figg, Nilofer Azad, Bradford J. Wood, James Doroshow & Elise C. Kohn. (2014) Phase I/Ib Study of Olaparib and Carboplatin in BRCA1 or BRCA2 Mutation-Associated Breast or Ovarian Cancer With Biomarker Analyses. JNCI: Journal of the National Cancer Institute 106:6.
Crossref
Crossref
Samir A. Farghaly. 2014. Advances in Diagnosis and Management of Ovarian Cancer. Advances in Diagnosis and Management of Ovarian Cancer
199
222
.
Gennaro Ilardi & Stefania Staibano. 2013. Prostate Cancer: Shifting from Morphology to Biology. Prostate Cancer: Shifting from Morphology to Biology
271
287
.
Curt Balch & Kenneth P. Nephew. 2013. Epigenetic Alterations in Oncogenesis. Epigenetic Alterations in Oncogenesis
285
311
.
Yong Tang, Hossein A. Hamed, Andrew Poklepovic, Yun Dai, Steven Grant & Paul Dent. (2012) Poly(ADP-ribose) Polymerase 1 Modulates the Lethality of CHK1 Inhibitors in Mammary Tumors. Molecular Pharmacology 82:2, pages 322-332.
Crossref
Crossref
Song-qiang Xie, Ya-hong Zhang, Qian Li, Feng-hua Xu, Jiu-wang Miao, Jin Zhao & Chao-jie Wang. (2012) 3-Nitro-naphthalimide and nitrogen mustard conjugate NNM-25 induces hepatocellular carcinoma apoptosis via PARP-1/p53 pathway. Apoptosis 17:7, pages 725-734.
Crossref
Crossref
Kristina Djinović-Carugo & Oliviero Carugo. 2012. Computational Medicine. Computational Medicine
145
158
.
M’Hammed Aguennouz, Gian Luca Vita, Sonia Messina, Annamaria Cama, Natalia Lanzano, Annamaria Ciranni, Carmelo Rodolico, Rosa Maria Di Giorgio & Giuseppe Vita. (2011) Telomere shortening is associated to TRF1 and PARP1 overexpression in Duchenne muscular dystrophy. Neurobiology of Aging 32:12, pages 2190-2197.
Crossref
Crossref
Fiona CHIONH, Gillian MITCHELL, Geoffrey J LINDEMAN, Michael FRIEDLANDER & Clare L SCOTT. (2011) The role of poly adenosine diphosphate ribose polymerase inhibitors in breast and ovarian cancer: Current status and future directions. Asia-Pacific Journal of Clinical Oncology 7:3, pages 197-211.
Crossref
Crossref
Juan Camilo Barreto-Andrade, Elena V. Efimova, Helena J. Mauceri, Michael A. Beckett, Harold G. Sutton, Thomas E. Darga, Everett E. Vokes, Mitchell C. Posner, Stephen J. Kron & Ralph R. Weichselbaum. (2011) Response of Human Prostate Cancer Cells and Tumors to Combining PARP Inhibition with Ionizing Radiation. Molecular Cancer Therapeutics 10:7, pages 1185-1193.
Crossref
Crossref
Y.H. Park, S.J. Lee, E.Y. Cho, Y.La. Choi, J.E. Lee, S.J. Nam, J.-H. Yang, J.H. Shin, E.Y. Ko, B.-K. Han, J.S. Ahn & Y.-H. Im. (2011) Clinical relevance of TNM staging system according to breast cancer subtypes. Annals of Oncology 22:7, pages 1554-1560.
Crossref
Crossref
Timothy A. Yap, Shahneen K. Sandhu, Craig P. Carden & Johann S. de Bono. (2011) Poly(ADP-Ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic. CA: A Cancer Journal for Clinicians 61:1, pages 31-49.
Crossref
Crossref
Clint Mitchell, Margaret Park, Patrick Eulitt, Chen Yang, Adly Yacoub & Paul Dent. (2010) Poly(ADP-Ribose) Polymerase 1 Modulates the Lethality of CHK1 Inhibitors in Carcinoma Cells. Molecular Pharmacology 78:5, pages 909-917.
Crossref
Crossref
Eitan Amir, Bostjan Seruga, Rosario Serrano & Alberto Ocana. (2010) Targeting DNA repair in breast cancer: A clinical and translational update. Cancer Treatment Reviews 36:7, pages 557-565.
Crossref
Crossref
Isabel M. Pires, Rachel Poole & Ester M. Hammond. 2010. Tumor Microenvironment. Tumor Microenvironment
207
228
.
Donald J. AbrahamGabriele Costantino & Roberto Pellicciari. 2003. Burger's Medicinal Chemistry and Drug Discovery. Burger's Medicinal Chemistry and Drug Discovery
151
174
.
Jin-xue He, Chun-hao Yang & Ze-hong Miao. (2010) Poly(ADP-ribose) polymerase inhibitors as promising cancer therapeutics. Acta Pharmacologica Sinica 31:9, pages 1172-1180.
Crossref
Crossref
Hiroaki Toshimitsu, Yasunori Yoshimoto, Christina K. Augustine, James C. Padussis, Jin S. Yoo, M. Angelica Selim, Scott K. Pruitt, Henry S. Friedman, Francis Ali-Osman & Douglas S. Tyler. (2010) Inhibition of Poly(ADP-Ribose) Polymerase Enhances the Effect of Chemotherapy in an Animal Model of Regional Therapy for the Treatment of Advanced Extremity Malignant Melanoma. Annals of Surgical Oncology 17:8, pages 2247-2254.
Crossref
Crossref
Elena V. Efimova, Helena J. Mauceri, Daniel W. Golden, Edwardine Labay, Vytautas P. Bindokas, Thomas E. Darga, Chaitali Chakraborty, Juan Camilo Barreto-Andrade, Clayton Crawley, Harold G. Sutton, Stephen J. Kron & Ralph R. Weichselbaum. (2010) Poly(ADP-Ribose) Polymerase Inhibitor Induces Accelerated Senescence in Irradiated Breast Cancer Cells and Tumors. Cancer Research 70:15, pages 6277-6282.
Crossref
Crossref
Johan Weigelt. (2010) Structural genomics?Impact on biomedicine and drug discovery. Experimental Cell Research 316:8, pages 1332-1338.
Crossref
Crossref
Donald J. AbrahamMatthieu Schapira. 2003. Burger's Medicinal Chemistry and Drug Discovery. Burger's Medicinal Chemistry and Drug Discovery
569
600
.
. (2010) Current World Literature. Current Opinion in Obstetrics & Gynecology 22:1, pages 87-93.
Crossref
Crossref
Giovanna Pescatore, Danila Branca, Fabrizio Fiore, Olaf Kinzel, Laura Llauger Bufi, Ester Muraglia, Federica Orvieto, Michael Rowley, Carlo Toniatti, Caterina Torrisi & Philip Jones. (2010) Identification and SAR of novel pyrrolo[1,2-a]pyrazin-1(2H)-one derivatives as inhibitors of poly(ADP-ribose) polymerase-1 (PARP-1). Bioorganic & Medicinal Chemistry Letters 20:3, pages 1094-1099.
Crossref
Crossref
Federica Ferrigno, Danila Branca, Olaf Kinzel, Samuele Lillini, Laura Llauger Bufi, Edith Monteagudo, Ester Muraglia, Michael Rowley, Carsten Schultz-Fademrecht, Carlo Toniatti, Caterina Torrisi & Philip Jones. (2010) Development of substituted 6-[4-fluoro-3-(piperazin-1-ylcarbonyl)benzyl]-4,5-dimethylpyridazin-3(2H)-ones as potent poly(ADP?ribose) polymerase-1 (PARP-1) inhibitors active in BRCA deficient cells. Bioorganic & Medicinal Chemistry Letters 20:3, pages 1100-1105.
Crossref
Crossref
Caterina Torrisi, Monica Bisbocci, Raffaele Ingenito, Jesus M. Ontoria, Michael Rowley, Carsten Schultz-Fademrecht, Carlo Toniatti & Philip Jones. (2010) Discovery and SAR of novel, potent and selective hexahydrobenzonaphthyridinone inhibitors of poly(ADP-ribose)polymerase-1 (PARP-1). Bioorganic & Medicinal Chemistry Letters 20:2, pages 448-452.
Crossref
Crossref
Rita Scarpelli, Julia K. Boueres, Mauro Cerretani, Federica Ferrigno, Jesus M. Ontoria, Michael Rowley, Carsten Schultz-Fademrecht, Carlo Toniatti & Philip Jones. (2010) Synthesis and biological evaluation of substituted 2-phenyl-2H-indazole-7-carboxamides as potent poly(ADP-ribose) polymerase (PARP) inhibitors. Bioorganic & Medicinal Chemistry Letters 20:2, pages 488-492.
Crossref
Crossref
Moïse Namer, Michel Héry, Marc Spielmann & Joseph GligorovT. Bachelot, S.-I. Labidi, O. Tredan, I. Ray-Coquard & J.-P. Guastalla. 2010. Cancer du sein en situation métastatique. Cancer du sein en situation métastatique
233
242
.
Philip Jones, Sergio Altamura, Julia Boueres, Federica Ferrigno, Massimiliano Fonsi, Claudia Giomini, Stefania Lamartina, Edith Monteagudo, Jesus M. Ontoria, Maria Vittoria Orsale, Maria Cecilia Palumbi, Silvia Pesci, Giuseppe Roscilli, Rita Scarpelli, Carsten Schultz-Fademrecht, Carlo Toniatti & Michael Rowley. (2009)
Discovery of 2-{4-[(3
S
)-Piperidin-3-yl]phenyl}-2
H
-indazole-7-carboxamide (MK-4827): A Novel Oral Poly(ADP-ribose)polymerase (PARP) Inhibitor Efficacious in BRCA-1 and -2 Mutant Tumors
. Journal of Medicinal Chemistry 52:22, pages 7170-7185.
Crossref
Crossref
Marie-Claude Beauchamp, Ariane Knafo, Amber Yasmeen, Joan M. Carboni, Marco M. Gottardis, Michael N. Pollak & Walter H. Gotlieb. (2009) BMS-536924 sensitizes human epithelial ovarian cancer cells to the PARP inhibitor, 3-aminobenzamide. Gynecologic Oncology 115:2, pages 193-198.
Crossref
Crossref
Danila Branca, Mauro Cerretani, Philip Jones, Uwe Koch, Federica Orvieto, Maria Cecilia Palumbi, Michael Rowley, Carlo Toniatti & Ester Muraglia. (2009) Identification of aminoethyl pyrrolo dihydroisoquinolinones as novel poly(ADP-ribose) polymerase-1 inhibitors. Bioorganic & Medicinal Chemistry Letters 19:15, pages 4042-4045.
Crossref
Crossref
Federica Orvieto, Danila Branca, Claudia Giomini, Philip Jones, Uwe Koch, Jesus M. Ontoria, Maria Cecilia Palumbi, Michael Rowley, Carlo Toniatti & Ester Muraglia. (2009) Identification of substituted pyrazolo[1,5-a]quinazolin-5(4H)-one as potent poly(ADP-ribose)polymerase-1 (PARP-1) inhibitors. Bioorganic & Medicinal Chemistry Letters 19:15, pages 4196-4200.
Crossref
Crossref